EGFR and glioblastoma: EGFR amplification (Amp) and mutations have been identified as driving events for multiple cancers, non-small cell lung cancer (NSCLC), breast cancer and GBM in particular (da Cunha et al., 2011; Brennan et al., 2013; Hsu and Hung, 2016; Sigismund et al., 2018).